Strength

規格

3mg

Product   License

A209041

Indications

適應癥

? Treatment   of mild to moderate active Crohn’s disease involving the ileum and/or   the ascending colon, in patients 8 years and older.

? Maintenance   of clinical remission of mild to moderate Crohn’s disease involving the   ileum and/or the ascending colon for up to 3 months in adults.

?治療8歲及以上患者中涉及回腸和/或升結腸的輕度至中度活動性克羅恩病。

?在成人中，涉及回腸和/或升結腸的輕度至中度克羅恩病的臨床緩解期長達3個月。

Approved Date

批準日期

09/28/2017

Market   Authorization Holder

持有人

Sciecure   Pharma Inc.